Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 224-235

  Lee, Seung Yup ^a   Lee, Soo Jung ^b   Han, Changsu ^c   Patkar, Ashwin A ^d   Masand, Prakash S ^e   Pae, Chi Un ^b,d  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Global Medical Education Inc   (United States)

Author keywords

Antidepressant; Depression; Novel target; Oxidative nitrosative stress

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; C REACTIVE PROTEIN; CARBAMAZEPINE; CATALASE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; GAMMA INTERFERON; IMIPRAMINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; LAMOTRIGINE; MOOD STABILIZER; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUPEROXIDE DISMUTASE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ACTION POTENTIAL; ARTICLE; CYTOKINE PRODUCTION; DEPRESSION; DNA MODIFICATION; ELECTRON TRANSPORT; ENDOPLASMIC RETICULUM; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; EXCITOTOXICITY; EXOCYTOSIS; HOMOZYGOSITY; HUMAN; IMMUNOGENICITY; LIFESPAN; MACROPHAGE ACTIVATION; MITOCHONDRIAL MEMBRANE; NEUROTRANSMITTER RELEASE; NITROSATIVE STRESS; NITROSYLATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

2,3-DIOXEGENASE; 5-HT; 5-HYDROXYTRYPTAMINE; ADENOSINE TRIPHOSPHATE; ANTIDEPRESSANT; ANTIOXIDANT RESPONSE ELEMENT; ARE; ATP; BDNF; BRAIN-DERIVED NEUROTROPHIC FACTOR; CAMP-RESPONSE ELEMENT-BINDING-PROTEIN (CREB); CAT; CATALASE; COX; CREB; CYCLOOXYGENASE; DEOXYRIBONUCLEIC ACID; DEPRESSION; DNA; EFE; ENDOPLASMIC RETICULUM; ER; ETHYL FERULATE (ETHYL 4-HYDROXY-3-METHOXYCINNAMATE); FA; FERULIC ACID (4-HYDROXY-3-METHOXYCINNAMIC ACID); FORCED SWIMMING TEST; FST; GLYCOGEN SYNTHASE KINASE 3; GSK3; HPA; HYPOTHALAMIC-PITUITARY-ADRENAL AXIS; IDO; INF-Γ; INTERFERON-GAMMA; N-ACETYLCYSTEINE; NAC; NAD; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE; NO; NO SYNTHASE; NOS; NOVEL TARGET; NRF2; NUCLEAR FACTOR E2-RELATED FACTOR 2; OXIDATIVE/NITROSATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RNS; ROS; SOD; SUPEROXIDE DISMUTASE; TAIL-SUSPENSION TEST; TST;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; HUMANS; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84883554467     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.09.008     Document Type: Article

References (164)

1. Abdel-Wahab B.A., Salama R.H. Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacol Biochem Behav 2011, 100:59-65.
2. Acuna-Castroviejo D., Martin M., Macias M., Escames G., Leon J., Khaldy H., et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001, 30:65-74.
3. Alle H., Roth A., Geiger J.R. Energy-efficient action potentials in hippocampal mossy fibers. Science 2009, 325:1405-1408.
4. Anselmi C., Centini M., Andreassi M., Buonocore A., La Rosa C., Facino R.M., et al. Conformational analysis: a tool for the elucidation of the antioxidant properties of ferulic acid derivatives in membrane models. J Pharm Biomed Anal 2004, 35:1241-1249.
5. Arora T., Mehta A.K., Sharma K.K., Mediratta P.K., Banerjee B.D., Garg G.R., et al. Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress in brain during chemical epileptogenesis in rats. Basic Clin Pharmacol Toxicol 2010, 106:372-377.
6. Attwell D., Laughlin S.B. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 2001, 21:1133-1145.
7. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012, 64:238-258.
8. Babson J.R., Gavitt N.E., Dougherty J.M. Chlorpromazine protection against Ca(2+)-dependent and oxidative cell injury. Limitations due to depressed mitochondrial function. Biochem Pharmacol 1994, 48:1509-1517.
9. Barakat D.J., Dvoriantchikova G., Ivanov D., Shestopalov V.I. Astroglial NF-kappaB mediates oxidative stress by regulation of NADPH oxidase in a model of retinal ischemia reperfusion injury. J Neurochem 2012, 120:586-597.
10. Beaulieu J.M., Zhang X., Rodriguiz R.M., Sotnikova T.D., Cools M.J., Wetsel W.C., et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008, 105:1333-1338.
11. Belanger M., Allaman I., Magistretti P.J. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011, 14:724-738.
12. Berk M., Dean O., Cotton S.M., Gama C.S., Kapczinski F., Fernandes B.S., et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011, 135:389-394.
13. Beurel E., Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006, 79:173-189.
14. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 64:43-51.
15. Bradley C.A., Peineau S., Taghibiglou C., Nicolas C.S., Whitcomb D.J., Bortolotto Z.A., et al. A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci 2012, 5:13.
16. Caldwell C.L., Irwin M., Lohr J. Reduced natural killer cell cytotoxicity in depression but not in schizophrenia. Biol Psychiatry 1991, 30:1131-1138.
17. Chiu H.J., Fischman D.A., Hammerling U. Vitamin A depletion causes oxidative stress, mitochondrial dysfunction, and PARP-1-dependent energy deprivation. FASEB J 2008, 22:3878-3887.
18. Correa F., Mallard C., Nilsson M., Sandberg M. Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3beta. Neurobiol Dis 2011, 44:142-151.
19. Cui J., Shao L., Young L.T., Wang J.F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007, 144:1447-1453.
20. Dakhale G., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
21. Dhir A., Kulkarni S.K. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 2007, 568:177-185.
22. Dieperink E., Ho S.B., Thuras P., Willenbring M.L. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44:104-112.
23. Dietrich-Muszalska A., Kontek B., Rabe-Jablonska J. Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro. Neuropsychobiology 2011, 63:197-201.
24. Doornbos B., van Goor S.A., Dijck-Brouwer D.A., Schaafsma A., Korf J., Muskiet F.A. Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:49-52.
25. Dwyer B.E., Nishimura R.N., Lu S.Y. Differential expression of heme oxygenase-1 in cultured cortical neurons and astrocytes determined by the aid of a new heme oxygenase antibody. Response to oxidative stress. Brain research. Mol Brain Res 1995, 30:37-47.
26. Eren I., Naziroglu M., Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res 2007, 32:1188-1195.
27. Eu J.P., Liu L., Zeng M., Stamler J.S. An apoptotic model for nitrosative stress. Biochemistry 2000, 39:1040-1047.
28. Evans D.L., Folds J.D., Petitto J.M., Golden R.N., Pedersen C.A., Corrigan M., et al. Circulating natural killer cell phenotypes in men and women with major depression. Relation to cytotoxic activity and severity of depression. Arch Gen Psychiatry 1992, 49:388-395.
29. Finkel M.S., Laghrissi-Thode F., Pollock B.G., Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996, 32:653-658.
30. Fisher M., Levine P.H., Weiner B.H., Johnson M.H., Doyle E.M., Ellis P.A., et al. Dietary n-3 fatty acid supplementation reduces superoxide production and chemiluminescence in a monocyte-enriched preparation of leukocytes. Am J Clin Nutr 1990, 51:804-808.
31. Fourcade S., Ruiz M., Guilera C., Hahnen E., Brichta L., Naudi A., et al. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet 2010, 19:2005-2014.
32. Freeman M.P., Davis M., Sinha P., Wisner K.L., Hibbeln J.R., Gelenberg A.J. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 2008, 110:142-148.
33. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006, 31:326-332.
34. Fujii H., Li S.H., Szmitko P.E., Fedak P.W., Verma S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2006, 26:2476-2482.
35. Fukuwatari T., Shibata K. Effect of nicotinamide administration on the tryptophan-nicotinamide pathway in humans. Int J Vitam Nutr Res 2007, 77:255-262.
36. Galecki P., Maes M., Florkowski A., Lewinski A., Galecka E., Bienkiewicz M., et al. Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J Affect Disord 2011, 129:175-182.
37. Gertsik L., Poland R.E., Bresee C., Rapaport M.H. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 2012, 32:61-64.
38. Ghribi O., Herman M.M., Savory J. Lithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation. J Neurosci Res 2003, 71:853-862.
39. Gossmann T.I., Ziegler M., Puntervoll P., de Figueiredo L.F., Schuster S., Heiland I. NAD biosynthesis and salvage - a phylogenetic perspective. FEBS J 2012, 279(18):3355-3363.
40. Graf W.D., Oleinik O.E., Glauser T.A., Maertens P., Eder D.N., Pippenger C.E. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics 1998, 29:195-201.
41. Gupta R.K., Kumar R., Bassett M. Interferon-induced depressive illness in hep C patients responds to SSRI antidepressant treatments. Neuropsychiatr Dis Treat 2006, 2:355-358.
42. Haddad J.J., Saade N.E., Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol 2002, 133:1-19.
43. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
44. He T., Katusic Z.S. Brain-derived neurotrophic factor increases expression of MnSOD in human circulating angiogenic cells. Microvasc Res 2012, 83(3):366-371.
45. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007, 38:247-252.
46. Hibbeln J.R., Ferguson T.A., Blasbalg T.L. Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation: opportunities for intervention. Int Rev Psychiatry 2006, 18:107-118.
47. Hu S., Begum A.N., Jones M.R., Oh M.S., Beech W.K., Beech B.H., et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 2009, 33:193-206.
48. Hurd R.W., Van Rinsvelt H.A., Wilder B.J., Karas B., Maenhaut W., De Reu L. Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects. Neurology 1984, 34:1393-1395.
49. Hwang J., Zheng L.T., Ock J., Lee M.G., Kim S.H., Lee H.W., et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008, 55:826-834.
50. Irwin M., Caldwell C., Smith T.L., Brown S., Schuckit M.A., Gillin J.C. Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity. Role of severity of depressive symptoms and alcohol consumption. Arch Gen Psychiatry 1990, 47:713-719.
51. Irwin M., Lacher U., Caldwell C. Depression and reduced natural killer cytotoxicity: a longitudinal study of depressed patients and control subjects. Psychol Med 1992, 22:1045-1050.
52. Johnson J.A., Johnson D.A., Kraft A.D., Calkins M.J., Jakel R.J., Vargas M.R., et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 2008, 1147:61-69.
53. Jope R.S. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 2011, 4:16.
54. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007, 32:577-595.
55. Jornada L.K., Valvassori S.S., Steckert A.V., Moretti M., Mina F., Ferreira C.L., et al. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res 2011, 45:162-168.
56. Karabiber H., Yakinci C., Durmaz Y., Temel I., Mehmet N. Serum nitrite and nitrate levels in epileptic children using valproic acid or carbamazepine. Brain Dev 2004, 26:15-18.
57. Khairova R., Pawar R., Salvadore G., Juruena M.F., de Sousa R.T., Soeiro-de-Souza M.G., et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep 2012, 5:680-682.
58. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002, 58:1-10.
59. Khanzode S.D., Dakhale G.N., Khanzode S.S., Saoji A., Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003, 8:365-370.
60. Khatua A.K., Bhattacharyya M. NADPH-induced oxidative damage of rat liver microsomes: protective role of chlorpromazine and trifluoperazine. Pol J Pharmacol 2001, 53:629-634.
61. Kim do H., Li H., Yoo K.Y., Lee B.H., Hwang I.K., Won M.H. Effects of fluoxetine on ischemic cells and expressions in BDNF and some antioxidants in the gerbil hippocampal CA1 region induced by transient ischemia. Exp Neurol 2007, 204:748-758.
62. Kobrosly R., van Wijngaarden E. Associations between immunologic, inflammatory, and oxidative stress markers with severity of depressive symptoms: an analysis of the 2005-2006 National Health and Nutrition Examination Survey. Neurotoxicology 2010, 31:126-133.
63. Kotan V.O., Sarandol E., Kirhan E., Ozkaya G., Kirli S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1284-1290.
64. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:744-759.
65. Kumar P., Kumar A. Protective role of sertraline against 3-nitropropionic acid-induced cognitive dysfunction and redox ratio in striatum, cortex and hippocampus of rat brain. Indian J Exp Biol 2009, 47:715-722.
66. Kurekci A.E., Alpay F., Tanindi S., Gokcay E., Ozcan O., Akin R., et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Epilepsia 1995, 36:600-604.
67. Lee Y.J., Choi B., Lee E.H., Choi K.S., Sohn S. Immobilization stress induces cell death through production of reactive oxygen species in the mouse cerebral cortex. Neurosci Lett 2006, 392:27-31.
68. Lee C.H., Park J.H., Yoo K.Y., Choi J.H., Hwang I.K., Ryu P.D., et al. Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. Exp Neurol 2011, 229:450-459.
69. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785.
70. Lesperance F., Frasure-Smith N., St-Andre E., Turecki G., Lesperance P., Wisniewski S.R. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 2011, 72:1054-1062.
71. Li X., Jope R.S. Is glycogen synthase kinase-3 a central modulator in mood regulation?. Neuropsychopharmacology 2010, 35:2143-2154.
72. Li Q., Zhao H.F., Zhang Z.F., Liu Z.G., Pei X.R., Wang J.B., et al. Long-term administration of green tea catechins prevents age-related spatial learning and memory decline in C57BL/6 J mice by regulating hippocampal cyclic amp-response element binding protein signaling cascade. Neuroscience 2009, 159:1208-1215.
73. Lin S.J., Shyue S.K., Hung Y.Y., Chen Y.H., Ku H.H., Chen J.W., et al. Superoxide dismutase inhibits the expression of vascular cell adhesion molecule-1 and intracellular cell adhesion molecule-1 induced by tumor necrosis factor-alpha in human endothelial cells through the JNK/p38 pathways. Arterioscler Thromb Vasc Biol 2005, 25:334-340.
74. Lu D.Y., Tsao Y.Y., Leung Y.M., Su K.P. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology 2010, 35:2238-2248.
75. Lu D.Y., Leung Y.M., Su K.P. Interferon-alpha induces nitric oxide synthase expression and haem oxygenase-1 down-regulation in microglia: implications of cellular mechanism of IFN-alpha-induced depression. Int J Neuropsychopharmacol 2012, 1-12.
76. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., da Silva Vargas R., et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36.
77. Maes M., Vandoolaeghe E., Neels H., Demedts P., Wauters A., Meltzer H.Y., et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997, 42:349-358.
78. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009, 30:462-469.
79. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:676-692.
80. Maes M., Kubera M., Obuchowiczwa E., Goehler L., Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011, 32:7-24.
81. Maes M., Leonard B., Fernandez A., Kubera M., Nowak G., Veerhuis R., et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:659-663.
82. Maes M., Ringel K., Kubera M., Berk M., Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 2012, 136:386-392.
83. Maes M, Mihaylova I, Kubera M, Leunis JC, Twisk FN, Geffard M. IgM-mediated autoimmune responses directed against anchorage epitopes are greater in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) than in major depression. Metab Brain Dis in press.
84. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20(3):127-150.
85. Magalhaes P.V., Dean O.M., Bush A.I., Copolov D.L., Malhi G.S., Kohlmann K., et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011, 33:374-378.
86. Maker H.S., Weiss C., Silides D.J., Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 1981, 36:589-593.
87. Makrides M., Gibson R.A., McPhee A.J., Yelland L., Quinlivan J., Ryan P. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA 2010, 304:1675-1683.
88. Marangell L.B., Martinez J.M., Zboyan H.A., Kertz B., Kim H.F., Puryear L.J. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003, 160:996-998.
89. Marnett L.J. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999, 424:83-95.
90. Martinez-Ballesteros C., Pita-Calandre E., Sanchez-Gonzalez Y., Rodriguez-Lopez C.M., Agil A. Lipid peroxidation in adult epileptic patients treated with valproic acid. Rev Neurol 2004, 38:101-106.
91. Meares G.P., Mines M.A., Beurel E., Eom T.Y., Song L., Zmijewska A.A., et al. Glycogen synthase kinase-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells. Exp Cell Res 2011, 317:1621-1628.
92. Meszaros Z.S., Perl A., Faraone S.V. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry 2012, 73(7):993-1001.
93. Miura H., Ozaki N., Sawada M., Isobe K., Ohta T., Nagatsu T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008, 11:198-209.
94. Moreno-Fernandez A.M., Cordero M.D., Garrido-Maraver J., Alcocer-Gomez E., Casas-Barquero N., Carmona-Lopez M.I., et al. Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. J Psychiatr Res 2012, 46:341-345.
95. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007, 12:988-1000.
96. Muller A., Cadenas E., Graf P., Sies H. A novel biologically active seleno-organic compound-I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol 1984, 33:3235-3239.
97. Na L., Wartenberg M., Nau H., Hescheler J., Sauer H. Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen species. Birth Defects Res A Clin Mol Teratol 2003, 67:174-180.
98. Nemets H., Nemets B., Apter A., Bracha Z., Belmaker R.H. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006, 163:1098-1100.
99. Niketic V., Ristic S., Saicic Z.S., Spasic M., Buzadzic B., Stojkovic M. Activities of antioxidant enzymes and formation of the glutathione adduct of hemoglobin (Hb ASSG) in epileptic patients with long-term antiepileptic therapy. Farmaco 1995, 50:811-813.
100. Nikushkin E.V., Bordiukov M.M. Antioxidative activity of drugs used in anticonvulsive therapy. Biull Eksp Biol Med 1993, 115:254-256.
101. Oh G.S., Pae H.O., Choi B.M., Chae S.C., Lee H.S., Ryu D.G., et al. 3-Hydroxyanthranilic acid, one of metabolites of tryptophan via indoleamine 2,3-dioxygenase pathway, suppresses inducible nitric oxide synthase expression by enhancing heme oxygenase-1 expression. Biochem Biophys Res Commun 2004, 320:1156-1162.
102. Okabe N., Nakamura T., Toyoshima T., Miyamoto O., Lu F., Itano T. Eicosapentaenoic acid prevents memory impairment after ischemia by inhibiting inflammatory response and oxidative damage. J Stroke Cerebrovasc Dis 2011, 20:188-195.
103. Pae C.U. Monocyte chemoattractant protein-1 (MCP1) may play a role in depression. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:313-314.
104. Pae C.U., Yu H.S., Kim T.S., Lee C.U., Lee S.J., Jun T.Y., et al. Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res 2004, 127:279-281.
105. Pae C.U., Marks D.M., Han C., Patkar A.A. Does minocycline have antidepressant effect?. Biomed Pharmacother 2008, 62:308-311.
106. Pae C.U., Marks D.M., Han C., Patkar A.A., Steffens D. Does neurotropin-3 have a therapeutic implication in major depression?. Int J Neurosci 2008, 118:1515-1522.
107. Pae C.U., Forbes A., Patkar A.A. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011, 25:109-127.
108. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003, 37:43-51.
109. Park S.W., Lee C.H., Lee J.G., Kim L.W., Shin B.S., Lee B.J., et al. Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells. Neurosci Res 2011, 69:283-290.
110. Parker G., Gibson N.A., Brotchie H., Heruc G., Rees A.M., Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006, 163:969-978.
111. Poeggeler B., Rassoulpour A., Wu H.Q., Guidetti P., Roberts R.C., Schwarcz R. Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-d-aspartate neurotoxicity. Neuroscience 2007, 148:188-197.
112. Posser T., Kaster M.P., Barauna S.C., Rocha J.B., Rodrigues A.L., Leal R.B. Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. Eur J Pharmacol 2009, 602:85-91.
113. Post A., Holsboer F., Behl C. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J Neurosci 1998, 18:8236-8246.
114. Raffa M., Atig F., Mhalla A., Kerkeni A., Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011, 11:124.
115. Raison C.L., Lowry C.A., Rook G.A. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry 2010, 67:1211-1224.
116. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6:219-233.
117. Razzoli M., Domenici E., Carboni L., Rantamaki T., Lindholm J., Castren E., et al. A role for BDNF/TrkB signaling in behavioral and physiological consequences of social defeat stress. Genes Brain Behav 2011, 10:424-433.
118. Requena J.R., Fu M.X., Ahmed M.U., Jenkins A.J., Lyons T.J., Thorpe S.R. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dial Transplant 1996, 11(Suppl. 5):48-53.
119. Reus G.Z., Stringari R.B., de Souza B., Petronilho F., Dal-Pizzol F., Hallak J.E., et al. Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxid Med Cell Longev 2010, 3:325-331.
120. Rogers P.J., Appleton K.M., Kessler D., Peters T.J., Gunnell D., Hayward R.C., et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008, 99:421-431.
121. Rondanelli M., Giacosa A., Opizzi A., Pelucchi C., La Vecchia C., Montorfano G., et al. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 2010, 29:55-64.
122. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231-1242.
123. Sarandol A., Sarandol E., Eker S.S., Erdinc S., Vatansever E., Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007, 22:67-73.
124. Satoh M.S., Poirier G.G., Lindahl T. NAD(+)-dependent repair of damaged DNA by human cell extracts. J Biol Chem 1993, 268:5480-5487.
125. Scapagnini G., Butterfield D.A., Colombrita C., Sultana R., Pascale A., Calabrese V. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Antioxid Redox Signal 2004, 6:811-818.
126. Scapagnini G., Colombrita C., Amadio M., D'Agata V., Arcelli E., Sapienza M., et al. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid Redox Signal 2006, 8:395-403.
127. Scapagnini G., Vasto S., Abraham N.G., Caruso C., Zella D., Fabio G. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 2011, 44:192-201.
128. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
129. Schulpis K.H., Lazaropoulou C., Regoutas S., Karikas G.A., Margeli A., Tsakiris S., et al. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 2006, 217:228-232.
130. Seckin S., Basaran-Kucukgergin C., Uysal M. Effect of acute and chronic administration of sodium valproate on lipid peroxidation and antioxidant system in rat liver. Pharmacol Toxicol 1999, 85:294-298.
131. Shelton R.C. The molecular neurobiology of depression. Psychiatr Clin North Am 2007, 30:1-11.
132. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011, 16:751-762.
133. Shivakumar B.R., Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 1993, 265:1137-1141.
134. Chemistry and metabolism of brain lipids. Basic neurochemistry 1981, Little, Brown & Co, Boston, MA. 3rd edition. G.J. Siegel, AR, B.W. Agranoff, R. Katzman (Eds.).
135. Simpson P.B., Russell J.T. Role of mitochondrial Ca2+ regulation in neuronal and glial cell signalling. Brain Res Brain Res Rev 1998, 26:72-81.
136. Song L., De Sarno P., Jope R.S. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 2002, 277:44701-44708.
137. Su K.P., Huang S.Y., Chiu C.C., Shen W.W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003, 13:267-271.
138. Tagliari B., Noschang C.G., Ferreira A.G., Ferrari O.A., Feksa L.R., Wannmacher C.M., et al. Chronic variable stress impairs energy metabolism in prefrontal cortex and hippocampus of rats: prevention by chronic antioxidant treatment. Metab Brain Dis 2010, 25:169-176.
139. Tagliari B., Scherer E.B., Machado F.R., Ferreira A.G., Dalmaz C., Wyse A.T. Antioxidants prevent memory deficits provoked by chronic variable stress in rats. Neurochem Res 2011, 36:2373-2380.
140. Tajalizadekhoob Y., Sharifi F., Fakhrzadeh H., Mirarefin M., Ghaderpanahi M., Badamchizade Z., et al. The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci 2011, 261:539-549.
141. Teyssier J.R., Ragot S., Donzel A., Chauvet-Gelinier J.C. Telomeres in the brain cortex of depressive patients. Encéphale 2010, 36:491-494.
142. Tung E.W., Winn L.M. Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. Mol Pharmacol 2011, 80:979-987.
143. Varoglu A.O., Yildirim A., Aygul R., Gundogdu O.L., Sahin Y.N. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance. Clin Neuropharmacol 2010, 33:155-157.
144. Vattakatuchery J.J., Rickards H., Cavanna A.E. Pathogenic mechanisms of depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci 2011, 23:261-276.
145. Verrotti A., Basciani F., Trotta D., Pomilio M.P., Morgese G., Chiarelli F. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1year of sodium valproate and carbamazepine therapy. Epilepsy Res 2002, 48:71-75.
146. Videbech P., Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004, 161:1957-1966.
147. Vismari L., Alves G.J., Muscara M.N., Palermo-Neto J. A possible role to nitric oxide in the anti-inflammatory effects of amitriptyline. Immunopharmacol Immunotoxicol 2012, 34:578-585.
148. Wei Z., Bai O., Richardson J.S., Mousseau D.D., Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res 2003, 73:364-368.
149. Wiseman H., Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996, 313(Pt 1):17-29.
150. Wolfs I.M., Donners M.M., de Winther M.P. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost 2011, 106:763-771.
151. Wolkowitz O.M., Mellon S.H., Epel E.S., Lin J., Dhabhar F.S., Su Y., et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress-preliminary findings. PLoS One 2011, 6:e17837.
152. Wolkowitz O.M., Mellon S.H., Epel E.S., Lin J., Reus V.I., Rosser R., et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol Psychiatry 2012, 17:164-172.
153. Xiong Z., Jiang B., Wu P.F., Tian J., Shi L.L., Gu J., et al. Antidepressant effects of a plant-derived flavonoid baicalein involving extracellular signal-regulated kinases cascade. Biol Pharm Bull 2011, 34:253-259.
154. Yang N.C., Lu L.H., Kao Y.H., Chau L.Y. Heme oxygenase-1 attenuates interleukin-1beta-induced nitric oxide synthase expression in vascular smooth muscle cells. J Biomed Sci 2004, 11:799-809.
155. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011, 15:2011-2035.
156. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000, 97:137-151.
157. Yao K., Fang J., Yin Y.L., Feng Z.M., Tang Z.R., Wu G. Tryptophan metabolism in animals: important roles in nutrition and health. Front Biosci (Schol Ed) 2011, 3:286-297.
158. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006, 81:291-300.
159. Zhang Z., Qin X., Zhao X., Tong N., Gong Y., Zhang W., et al. Valproic acid regulates antioxidant enzymes and prevents ischemia/reperfusion injury in the rat retina. Curr Eye Res 2012, 37:429-437.
160. Zhao Z., Wang W., Guo H., Zhou D. Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats. Behav Brain Res 2008, 194:108-113.
161. Zhou L., Zhu D.Y. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009, 20:223-230.
162. Zhou Q.G., Hu Y., Wu D.L., Zhu L.J., Chen C., Jin X., et al. Hippocampal telomerase is involved in the modulation of depressive behaviors. J Neurosci 2011, 31:12258-12269.
163. Zomkowski A.D., Engel D., Gabilan N.H., Rodrigues A.L. Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. Eur Neuropsychopharmacol 2010, 20:793-801.
164. Zunszain P.A., Anacker C., Cattaneo A., Choudhury S., Musaelyan K., Myint A.M., et al. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012, 37:939-949.